Asset
Sendegobresib
C4 Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05355753 | phase1 | terminated | 2022-03-25 | 2023-12-19 | C4 Therapeutics, Inc. | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors |
FDA applications (0)
This company has no applications containing this asset.